The Claim
In mice fed a high-fat diet, treatment with GW501516 is associated with upregulation of the PGC-1α–lipin 1–PPARα signaling axis in the liver, characterized by increased PPARα expression, enhanced DNA binding activity of PPARα, and elevated expression of downstream genes involved in fatty acid oxidation.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In mice eating a fatty diet, a drug called GW501516 seems to turn on a chain reaction in the liver that helps burn fat more efficiently.
See the scientific wording
In mice fed a high-fat diet, GW501516 treatment is associated with upregulation of the PGC-1α–lipin 1–PPARα signaling axis in the liver, including increased PPARα expression, DNA binding activity, and expression of downstream fatty acid oxidation genes.
What the research says
1 studyThe study shows that GW501516 helps turn on a liver pathway that burns fat in mice on a high-fat diet, exactly as the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.